Hormonal Therapies in Prostatic Cancer

Twenty-one patients with metastatic prostate cancer who had become refractory to hormonal therapies received lonidamine (150 mg tid and 600 mg daily dose in 17 and 4 patients, respectively). In all but 4 patients, treatment was continued until disease progression or the development of severe toxicity. Toxicity was minimal and reversible (score 1 or 2) and included myalgia (8 cases), arthralgia (6 cases), gastrointestinal toxicity (11 cases), fatigue (14 cases) and testicular pain (9 cases). The response was evaluated after at least one month of therapy with lonidamine, according to NPCP-USA recommendations. Of 21 patients who entered the study, only 15 were evaluable for response; 2 died (1 for severe toxicity and 1 for drug-unrelated reasons). No objective response was obtained in the series. In fact, only 6 patients achieved stable disease and 9 progressed. Median survival time from the beginning of treatment was no longer than that of patients in a similar condition who were treated with standard palliative maneuvers. We conclude that this therapeutic approach with lonidamine is not active in hormone-refractory prostatic cancer patients with distant metastasis.

Download Full-text

Hormonal therapies in prostatic cancer

Journal of Steroid Biochemistry ◽

10.1016/0022-4731(87)91655-4 ◽

1987 ◽

Vol 28 ◽

pp. 205

Author(s):

G.P. Murphy

Keyword(s):

Prostatic Cancer ◽

Hormonal Therapies

Download Full-text

The Ultrastructure of Metastatic Human Mammary Carcinoma After Prolonged Estrogen Therapy

Proceedings, annual meeting, Electron Microscopy Society of America ◽

10.1017/s042482010006091x ◽

1967 ◽

Vol 25 ◽

pp. 180-181

Author(s):

John H.L. Watson ◽

John L. Swedo ◽

R.W. Talley

Keyword(s):

Mammary Carcinoma ◽

Osmium Tetroxide ◽

Estrogen Therapy ◽

Ultrastructural Level ◽

Uranyl Acetate ◽

Human Mammary Carcinoma ◽

Surgical Biopsy ◽

Lead Hydroxide ◽

Preliminary Study ◽

Hormonal Therapies

A preliminary study of human mammary carcinoma on the ultrastructural level is reported for a metastatic, subcutaneous nodule, obtained as a surgical biopsy. The patient's tumor had responded favorably to a series of hormonal therapies, including androgens, estrogens, progestins, and corticoids for recurring nodules over eight years. The pertinent nodule was removed from the region of the gluteal maximus, two weeks following stilbestrol therapy. It was about 1.5 cms in diameter, and was located within the dermis. Pieces from it were fixed immediately in cold fixatives: phosphate buffered osmium tetroxide, glutaraldehyde, and paraformaldehyde. Embedment in each case was in Vestopal W. Contrasting was done with combinations of uranyl acetate and lead hydroxide.

Download Full-text